KR20020073182A - 칼슘 디카르복실레이트 에테르, 이의 제조 방법 및 이에의한 혈관 질환 및 당뇨병의 치료 방법 - Google Patents

칼슘 디카르복실레이트 에테르, 이의 제조 방법 및 이에의한 혈관 질환 및 당뇨병의 치료 방법 Download PDF

Info

Publication number
KR20020073182A
KR20020073182A KR1020027009519A KR20027009519A KR20020073182A KR 20020073182 A KR20020073182 A KR 20020073182A KR 1020027009519 A KR1020027009519 A KR 1020027009519A KR 20027009519 A KR20027009519 A KR 20027009519A KR 20020073182 A KR20020073182 A KR 20020073182A
Authority
KR
South Korea
Prior art keywords
methyl
hexyloxy
carboxy
compound
dimethylhexanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020027009519A
Other languages
English (en)
Korean (ko)
Inventor
하워드 요시히사 안도
도날드 유진 버틀러
게리 제이. 도즈먼
Original Assignee
워너-램버트 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 워너-램버트 캄파니 filed Critical 워너-램버트 캄파니
Publication of KR20020073182A publication Critical patent/KR20020073182A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/305—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020027009519A 2000-01-25 2001-01-11 칼슘 디카르복실레이트 에테르, 이의 제조 방법 및 이에의한 혈관 질환 및 당뇨병의 치료 방법 Ceased KR20020073182A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17782300P 2000-01-25 2000-01-25
US60/177,823 2000-01-25
PCT/IB2001/000026 WO2001055078A1 (en) 2000-01-25 2001-01-11 Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith

Publications (1)

Publication Number Publication Date
KR20020073182A true KR20020073182A (ko) 2002-09-19

Family

ID=22650106

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027009519A Ceased KR20020073182A (ko) 2000-01-25 2001-01-11 칼슘 디카르복실레이트 에테르, 이의 제조 방법 및 이에의한 혈관 질환 및 당뇨병의 치료 방법

Country Status (39)

Country Link
EP (1) EP1259474B1 (enExample)
JP (1) JP4750995B2 (enExample)
KR (1) KR20020073182A (enExample)
CN (1) CN1395555A (enExample)
AP (1) AP2002002587A0 (enExample)
AR (1) AR029436A1 (enExample)
AT (1) ATE431326T1 (enExample)
AU (1) AU2214001A (enExample)
BG (1) BG106851A (enExample)
BR (1) BR0107763A (enExample)
CA (1) CA2397960C (enExample)
CO (1) CO5261537A1 (enExample)
CZ (1) CZ20022474A3 (enExample)
DE (1) DE60138686D1 (enExample)
DK (1) DK1259474T3 (enExample)
DZ (1) DZ3239A1 (enExample)
EA (1) EA004862B1 (enExample)
EE (1) EE200200404A (enExample)
ES (1) ES2324281T3 (enExample)
GE (1) GEP20053428B (enExample)
GT (1) GT200100015A (enExample)
HN (1) HN2001000011A (enExample)
HU (1) HUP0204422A3 (enExample)
IL (1) IL150541A0 (enExample)
IS (1) IS6442A (enExample)
MA (1) MA26867A1 (enExample)
MX (1) MXPA02007223A (enExample)
NO (1) NO20023526L (enExample)
NZ (1) NZ519550A (enExample)
OA (1) OA12166A (enExample)
PA (1) PA8510601A1 (enExample)
PE (1) PE20011064A1 (enExample)
PL (1) PL357076A1 (enExample)
SK (1) SK10622002A3 (enExample)
SV (1) SV2002000290A (enExample)
TN (1) TNSN01013A1 (enExample)
UY (1) UY26550A1 (enExample)
WO (1) WO2001055078A1 (enExample)
ZA (1) ZA200205880B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1045691T1 (en) * 1997-12-12 2005-04-30 Warner-Lambert Company Llc Statin-carboxyalkylether combinations
BR0313883A (pt) * 2002-08-22 2005-07-19 Warner Lambert Co Método de tratar osteoartrite
KR20080007315A (ko) * 2005-04-19 2008-01-18 에자이 알앤드디 매니지먼트 가부시키가이샤 비스[(2ｓ)-3-[3-[(2ｓ)-3-(4-클로로-2-시아노페녹시)-2-플루오로프로폭시]페닐]-2-이소프로폭시프로피온산]칼슘 및그 중간체
US7816405B2 (en) 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
CN111704543A (zh) * 2014-11-14 2020-09-25 燿石治疗公司 用于制备α,ω-二羧酸封端的二烷醚的方法和中间体
US20180297929A1 (en) * 2017-04-18 2018-10-18 Gemphire Therapeutics Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
WO2020081837A1 (en) * 2018-10-18 2020-04-23 Gemphire Therapeutics Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
NZ503982A (en) 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
EE200200404A (et) 2003-10-15
AR029436A1 (es) 2003-06-25
DZ3239A1 (fr) 2001-08-02
OA12166A (en) 2003-11-07
HUP0204422A2 (en) 2003-05-28
GEP20053428B (en) 2005-01-25
JP2003520835A (ja) 2003-07-08
CZ20022474A3 (cs) 2003-06-18
EP1259474A1 (en) 2002-11-27
BG106851A (en) 2003-01-31
AU2214001A (en) 2001-08-07
SK10622002A3 (sk) 2003-07-01
EP1259474B1 (en) 2009-05-13
TNSN01013A1 (fr) 2005-11-10
EA200200641A1 (ru) 2002-12-26
IS6442A (is) 2002-06-25
ES2324281T3 (es) 2009-08-04
HN2001000011A (es) 2001-06-13
ZA200205880B (en) 2003-07-23
WO2001055078A1 (en) 2001-08-02
GT200100015A (es) 2001-10-19
BR0107763A (pt) 2002-11-12
DK1259474T3 (da) 2009-07-20
MXPA02007223A (es) 2002-11-29
HUP0204422A3 (en) 2003-08-28
SV2002000290A (es) 2002-07-16
DE60138686D1 (de) 2009-06-25
MA26867A1 (fr) 2004-12-20
EA004862B1 (ru) 2004-08-26
ATE431326T1 (de) 2009-05-15
NZ519550A (en) 2003-11-28
PE20011064A1 (es) 2001-10-22
CA2397960C (en) 2008-09-09
PL357076A1 (en) 2004-07-12
IL150541A0 (en) 2003-02-12
CN1395555A (zh) 2003-02-05
UY26550A1 (es) 2001-08-27
NO20023526D0 (no) 2002-07-24
PA8510601A1 (es) 2002-08-26
JP4750995B2 (ja) 2011-08-17
NO20023526L (no) 2002-08-27
CO5261537A1 (es) 2003-03-31
CA2397960A1 (en) 2001-08-02
AP2002002587A0 (en) 2002-09-30

Similar Documents

Publication Publication Date Title
CA2516471C (en) Ferric organic compounds, uses thereof and methods of making same
CN101337932A (zh) 喹啉羧酰胺的甲磺酸盐的结晶(b)及其制备方法
US7141608B2 (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
KR20020073182A (ko) 칼슘 디카르복실레이트 에테르, 이의 제조 방법 및 이에의한 혈관 질환 및 당뇨병의 치료 방법
US20040192655A1 (en) Risedronate sodium having a very low content of iron
EP3792258B1 (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
KR20080104063A (ko) 치환 페닐알칸산의 신규 결정 및 제조 방법
EP4055000B1 (en) Process for the preparation of ferric organic compounds
US20220169603A1 (en) Novel salts, crystalline forms and premix of hypolipidemic agent
WO2025141518A1 (en) Crystalline polymorphic forms of marimastat, an amorphous form of marimastat, processes for their preparation, pharmaceutical compositions comprising the same, and uses thereof
HK40106546A (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
CN110938001A (zh) 绿原酸乙醇胺盐及用途
HK40042284B (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
HK1050183A (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20020724

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20020903

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050429

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20050929

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20050429

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I